FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177789215> ?p ?o ?g. }

• W3177789215 endingPage "1150" @default.
• W3177789215 startingPage "1150" @default.
• W3177789215 abstract "Abstract Background: Ovarian cancer is the most lethal of all gynecologic malignancies with a grim 5-year survival rate of ~47%. Mortality occurs in the setting of recurrent disease wherein the co-presentation of chemoresistance and carcinomatosis limits the value of standard of care. It is therefore imperative to develop approaches that can prevent recurrent ovarian cancer. Oncolytic viruses are genetically modified replication competent viruses that can selectively infect cancer cells to induce cell lysis and death. This approach has proven to be clinically safe making it a promising approach to complement standard of care. The objective of this study is to evaluate the efficacy of CARG-2020, a virus-like vesicles (VLV) delivering three immune-modulators including IL-12, IL-17 antagonist and shRNA-PD-L1 in preventing recurrent disease in a syngeneic mouse model of recurrent ovarian cancer. Materials and Methods: In vitro: Triple knockout (TKO; p53LSL-R172H/Dicerflox/flox/Ptenflox/flox) mouse ovarian cancer cells were seeded in 96-well plates and treated with different doses of CARG-2020. Cell death was determined using the Incucyte imaging system. In vivo: TKO ovarian cancer cells stably expressing the mCherry fluorescent protein were injected i.p. in C57bl/6 mice (day 0) to mimic the establishment of recurrent disease. Treatment commenced on day 3 with the treatment group receiving three doses of 1x10^8 PFU of CARG-2020 given every other day (n=5). Control group received PBS (n=5). Both treatments were given i.p. Tumor growth was monitored by live imaging using mCherry fluorescence ROI area. Progression-free survival (PFS) was defined as the day ROI area reached 2,000. Results: CARG-2020 (1x10^5 PFU) demonstrated cytolytic effect in vitro and induced 100% cell death within 24h. In vivo, CARG-2020 induced significant decrease in i.p. tumor growth (p = 0.0128) compared to PBS control. Treatment with CARG-2020 completely delayed the establishment of recurrent disease (PFS, p = 0.0003). Whereas PBS control group demonstrated median PFS of 20 days, mice in the CARG-2020 group remained disease-free until day 60. Conclusion: CARG-2020 is able to prevent the establishment of recurrent disease in a syngeneic mouse model of recurrent ovarian cancer. Our results provide rationale for the further development of this platform as a therapeutic modality for ovarian cancer patients. Citation Format: Ayesha B. Alvero, Alexandra Fox, Bhaskara Madina, Valerian Nakaar, Timur Yarovinsky, Marie Krady, Bijan Almassian, Gil Mor. CARG-2020 artificial oncolytic virus delivering three immune-modulators prevents tumor recurrence in a syngeneic model of ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1150." @default.
• W3177789215 created "2021-07-19" @default.
• W3177789215 creator A5015746736 @default.
• W3177789215 creator A5024783851 @default.
• W3177789215 creator A5046448602 @default.
• W3177789215 creator A5050088263 @default.
• W3177789215 creator A5078106091 @default.
• W3177789215 creator A5081977424 @default.
• W3177789215 creator A5087192053 @default.
• W3177789215 creator A5088903979 @default.
• W3177789215 date "2021-07-01" @default.
• W3177789215 modified "2023-09-27" @default.
• W3177789215 title "Abstract 1150: CARG-2020 artificial oncolytic virus delivering three immune-modulators prevents tumor recurrence in a syngeneic model of ovarian cancer" @default.
• W3177789215 doi "https://doi.org/10.1158/1538-7445.am2021-1150" @default.
• W3177789215 hasPublicationYear "2021" @default.
• W3177789215 type Work @default.
• W3177789215 sameAs 3177789215 @default.
• W3177789215 citedByCount "0" @default.
• W3177789215 crossrefType "journal-article" @default.
• W3177789215 hasAuthorship W3177789215A5015746736 @default.
• W3177789215 hasAuthorship W3177789215A5024783851 @default.
• W3177789215 hasAuthorship W3177789215A5046448602 @default.
• W3177789215 hasAuthorship W3177789215A5050088263 @default.
• W3177789215 hasAuthorship W3177789215A5078106091 @default.
• W3177789215 hasAuthorship W3177789215A5081977424 @default.
• W3177789215 hasAuthorship W3177789215A5087192053 @default.
• W3177789215 hasAuthorship W3177789215A5088903979 @default.
• W3177789215 hasConcept C121608353 @default.
• W3177789215 hasConcept C126322002 @default.
• W3177789215 hasConcept C143998085 @default.
• W3177789215 hasConcept C173396325 @default.
• W3177789215 hasConcept C190283241 @default.
• W3177789215 hasConcept C203014093 @default.
• W3177789215 hasConcept C2780427987 @default.
• W3177789215 hasConcept C502942594 @default.
• W3177789215 hasConcept C55493867 @default.
• W3177789215 hasConcept C71924100 @default.
• W3177789215 hasConcept C82210918 @default.
• W3177789215 hasConcept C86803240 @default.
• W3177789215 hasConcept C8891405 @default.
• W3177789215 hasConceptScore W3177789215C121608353 @default.
• W3177789215 hasConceptScore W3177789215C126322002 @default.
• W3177789215 hasConceptScore W3177789215C143998085 @default.
• W3177789215 hasConceptScore W3177789215C173396325 @default.
• W3177789215 hasConceptScore W3177789215C190283241 @default.
• W3177789215 hasConceptScore W3177789215C203014093 @default.
• W3177789215 hasConceptScore W3177789215C2780427987 @default.
• W3177789215 hasConceptScore W3177789215C502942594 @default.
• W3177789215 hasConceptScore W3177789215C55493867 @default.
• W3177789215 hasConceptScore W3177789215C71924100 @default.
• W3177789215 hasConceptScore W3177789215C82210918 @default.
• W3177789215 hasConceptScore W3177789215C86803240 @default.
• W3177789215 hasConceptScore W3177789215C8891405 @default.
• W3177789215 hasIssue "13_Supplement" @default.
• W3177789215 hasLocation W31777892151 @default.
• W3177789215 hasOpenAccess W3177789215 @default.
• W3177789215 hasPrimaryLocation W31777892151 @default.
• W3177789215 hasRelatedWork W1995029154 @default.
• W3177789215 hasRelatedWork W2041267103 @default.
• W3177789215 hasRelatedWork W2070624905 @default.
• W3177789215 hasRelatedWork W2571047848 @default.
• W3177789215 hasRelatedWork W2801067660 @default.
• W3177789215 hasRelatedWork W2971454460 @default.
• W3177789215 hasRelatedWork W3048341121 @default.
• W3177789215 hasRelatedWork W3084364727 @default.
• W3177789215 hasRelatedWork W3092211482 @default.
• W3177789215 hasRelatedWork W4317486526 @default.
• W3177789215 hasVolume "81" @default.
• W3177789215 isParatext "false" @default.
• W3177789215 isRetracted "false" @default.
• W3177789215 magId "3177789215" @default.
• W3177789215 workType "article" @default.